{
    "organizations": [],
    "uuid": "ee745b9175543d7491e3bd4bde6f85cd93a8c679",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kadmon-posts-positive-topline-resu/brief-kadmon-posts-positive-topline-results-from-phase-2-study-of-kd025-in-idiopathic-pulmonary-fibrosis-idUSFWN1Q21DU",
    "ord_in_thread": 0,
    "title": "BRIEF-Kadmon Posts Positive Topline Results From Phase 2 Study Of KD025 In Idiopathic Pulmonary Fibrosis",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 12 (Reuters) - Kadmon Holdings Inc:\n* KADMON ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 STUDY OF KD025 IN IDIOPATHIC PULMONARY FIBROSIS\n* KADMON HOLDINGS INC - ‍KD025 WAS WELL TOLERATED AND DEMONSTRATED CLINICAL BENEFIT​\n* KADMON HOLDINGS INC - ‍KD025 HAD NO DRUG-RELATED SERIOUS ADVERSE EVENTS IN PHASE 2 STUDY​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-13T05:11:00.000+02:00",
    "crawled": "2018-02-13T16:01:43.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "kadmon",
        "holding",
        "inc",
        "kadmon",
        "announces",
        "positive",
        "topline",
        "result",
        "phase",
        "study",
        "kd025",
        "idiopathic",
        "pulmonary",
        "fibrosis",
        "kadmon",
        "holding",
        "inc",
        "well",
        "tolerated",
        "demonstrated",
        "clinical",
        "kadmon",
        "holding",
        "inc",
        "serious",
        "adverse",
        "event",
        "phase",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}